Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the pancreas that is surgically inoperable

- Must have had one prior chemotherapeutic regimen for advanced disease (Prior
radiation with a radiation sensitizer for locally advanced disease or adjuvant
therapy is not considered a prior regimen for purpose of this study)

- Disease must be measurable by RECIST criteria; measurable disease will be defined as
at least one lesion that can be accurately measured in at least one dimension
measuring at least 2 cm conventional CT or MRI or 1 cm with spiral CT scans (Appendix
A)

- Aged 18 years or older

- ECOG performance status of 0 – 2 (see Appendix B)

- Able to take oral medications without difficulty

- Adequate bone marrow function as evidenced by an ANC > 1500/mL and platelet count >
100, 000/mL

- Adequate renal function as evidenced by serum creatinine within institutional limits
or creatinine clearance > 60 ml/minute if above upper institutional limits (ULN)

- Adequate hepatic function as evidenced by ALT, AST, and total bilirubin within ULN.
If hepatic metastases are present, ALT and AST may be up to 5 x ULN.

- Provision of written informed consent

- Men and women of childbearing potential must be willing to practice acceptable
methods of birth control to prevent pregnancy. This is a precautionary measure for
use of Gefitinib and docetaxel.

Exclusion Criteria:

- Known severe hypersensitivity to Gefitinib or docetaxel or any of the excipients of
these products (i.e. polysorbate 80)

- Previous treatment with Gefitinib or docetaxel.

- Other coexisting malignancies or malignancies diagnosed within the last 5 years, with
the exception of basal cell carcinoma or squamous cell carcinoma of the skin or
cervical cancer in situ.

- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,
or St John's Wort

- Treatment with a non-approved or investigational drug within 30 days before Day 1 of
trial treatment.

- Treatment with radiation therapy or chemotherapy within 28 days before Day 1 of trial
treatment

- Any unresolved chronic toxicity greater then CTC grade 2 from previous anticancer
therapy (except alopecia)

- Incomplete healing from previous oncologic or other major surgery.

- Pregnancy or breast feeding (women of childbearing potential).

- Any evidence of clinically active interstitial lung disease (patients with chronic
stable radiographic changes who are asymptomatic need not be excluded).

- As judged by the investigator, any evidence of severe or uncontrolled systemic
disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal
disease).

- Evidence of any other significant clinical disorder or laboratory finding that makes
it undesirable for the subject to participate in the trial.